Get the Stockscreener App
123.17
1.47%
1.795
State Street Spdr S P Biotech Etf Stock (XBI) Forecast
The State Street Spdr S P Biotech Etf (XBI) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $119.91, representing a -2.64% decrease from the current price of $123.17. The highest analyst price target is $126.41, and the lowest is $113.41.
Note: Our forecast model does not currently account for dividend and stock split events. This means that our forecast may not be accurate for stocks that have recently experienced either of these events.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month XBI Price Target
Average 145.90
(+18.46% Upside)
Is State Street Spdr S P Biotech Etf (XBI) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 76.99 | Sell |
| STOCH(9,6) | 86.33 | Sell |
| STOCHRSI(14) | 100.00 | Sell |
| MACD(12,26) | 3.5514 | Buy |
| ADX(14) | 34.43 | Buy |
| William %R | -0.0296 | Sell |
| CCI(14) | 145.16 | Buy |
Buy: 3
Sell: 4
Neutral: 0
Summary: Sell
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
116.51
Buy
|
117.38
Buy
|
| MA20 |
113.66
Buy
|
114.51
Buy
|
| MA50 |
107.89
Buy
|
108.35
Buy
|
| MA100 |
98.60
Buy
|
101.60
Buy
|
| MA200 |
90.63
Buy
|
96.92
Buy
|
Buy: 10
Sell: 0
Neutral: 0
Summary: Buy
According to our latest analysis, XBI could be considered a Strong Buy, with 17 technical analysis indicators signaling 13 Buy signals, 4 signaling Sell signals and 0 Neutral signals. This might be a good time to open fresh positions on XBI, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 76.99 indicates that XBI is overbought. This suggests that XBI price has experienced a significant increase over a specified lookback period, potentially leading to a correction.
- STOCH (Stochastic Oscillator): The STOCH value of 86.33 indicates that XBI is oversold. This means that XBI price is at or near the highest level over a specified lookback period.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 100 indicates that XBI is oversold. This suggests that XBI price is at or near the highest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 34.43 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 145.16 indicates that XBI is overbought. This means that the price has moved significantly higher than its average, indicating a potential selling opportunity.
Long-term XBI price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about State Street Spdr S P Biotech Etf financial reports and earnings history, State Street Spdr S P Biotech Etf (XBI) stock could reach $91.93 by 2030, $93.79 by 2040 and $110.93 by 2050. See the projected annual prices until 2050 of the State Street Spdr S P Biotech Etf stock below:
- State Street Spdr S P Biotech Etf (XBI) is expected to reach an average price of $81.02 in 2035, with a high prediction of $81.89 and a low estimate of $71.16. This indicates an $-34.22% rise from the last recorded price of $123.17.
- State Street Spdr S P Biotech Etf (XBI) stock is projected to chart a bullish course in 2040, with an average price target of $91.19, representing an $-25.96% surge from its current level. The forecast ranges from a conservative $85.73 to a sky-high $93.79.
- Our analysts predict State Street Spdr S P Biotech Etf (XBI) to jump -23.93% by 2045, soaring from $89.55 to an average price of $93.69, potentially reaching $103.34. While $89.55 is the low estimate, the potential upside is significant.
- State Street Spdr S P Biotech Etf (XBI) stock is expected to climb by 2050, reaching an average of $110.31, a $-10.44% jump from its current level. However, a wide range of estimates exists, with high and low targets of $110.93 and $98.49, respectively, highlighting the market's uncertainty.
State Street Spdr S P Biotech Etf Stock (XBI) Year by Year Forecast
State Street Spdr S P Biotech Etf Stock (XBI) Price Forecast for 2025
State Street Spdr S P Biotech Etf Stock (XBI) is expected to reach an average price of $96.46 in 2025, with a high prediction of $126.41 and a low estimate of $66.51. This indicates an -21.68% fall from the last recorded price of $123.17.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| December, 2025 | $116.36 | $113.41 | $126.41 | -5.53% |
State Street Spdr S P Biotech Etf Stock (XBI) Price Forecast for 2026
The predicted value for State Street Spdr S P Biotech Etf (XBI) in 2026 is set at an average of $146.02. Estimates vary from a peak of $178.39 to a trough of $113.66, indicating an +18.56% surge from the present price of $123.17.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $135.07 | $113.66 | $135.13 | +9.67% |
| February, 2026 | $151.13 | $133.35 | $153.51 | +22.71% |
| March, 2026 | $155.32 | $142.50 | $159.42 | +26.11% |
| April, 2026 | $162.67 | $152.41 | $178.39 | +32.07% |
| May, 2026 | $148.67 | $132.04 | $162.95 | +20.71% |
| June, 2026 | $133.23 | $129.86 | $151.99 | +8.17% |
| July, 2026 | $130.52 | $121.83 | $144.48 | +5.98% |
| August, 2026 | $139.41 | $127.43 | $140.06 | +13.19% |
| September, 2026 | $137.41 | $131.85 | $145.11 | +11.56% |
| October, 2026 | $131.07 | $124.23 | $138.25 | +6.42% |
| November, 2026 | $136.38 | $122.10 | $137.21 | +10.73% |
| December, 2026 | $129.33 | $128.92 | $140.22 | +5.00% |
State Street Spdr S P Biotech Etf Stock (XBI) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for State Street Spdr S P Biotech Etf (XBI) is $101.91, with a high forecast of $138.41 and a low forecast of $65.41. This indicates an -17.26% decrease from the last price of $123.17.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $127.85 | $125.38 | $131.90 | +3.80% |
| February, 2027 | $125.54 | $125.01 | $138.41 | +1.93% |
| March, 2027 | $119.23 | $110.50 | $126.28 | -3.19% |
| April, 2027 | $104.11 | $99.39 | $122.83 | -15.47% |
| May, 2027 | $94.42 | $87.52 | $102.59 | -23.34% |
| June, 2027 | $87.53 | $85.34 | $102.79 | -28.93% |
| July, 2027 | $93.51 | $83.97 | $98.19 | -24.08% |
| August, 2027 | $83.47 | $83.29 | $100.82 | -32.23% |
| September, 2027 | $74.73 | $65.41 | $85.43 | -39.33% |
| October, 2027 | $71.25 | $65.77 | $78.31 | -42.15% |
| November, 2027 | $88.07 | $72.29 | $88.27 | -28.49% |
| December, 2027 | $97.42 | $81.73 | $98.82 | -20.90% |
State Street Spdr S P Biotech Etf Stock (XBI) Price Forecast for 2028
In 2028, State Street Spdr S P Biotech Etf (XBI) is projected to reach an average price of $87.44, with a high projection of $98.78 and a low estimate of $76.10. This indicates an -29.00% fall from the last price of $123.17.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $87.37 | $85.61 | $98.78 | -29.06% |
| February, 2028 | $82.97 | $78.62 | $92.47 | -32.64% |
| March, 2028 | $85.80 | $79.72 | $87.89 | -30.34% |
| April, 2028 | $84.71 | $80.76 | $90.15 | -31.22% |
| May, 2028 | $84.53 | $82.41 | $89.49 | -31.37% |
| June, 2028 | $90.65 | $81.76 | $93.28 | -26.40% |
| July, 2028 | $89.28 | $88.30 | $96.26 | -27.51% |
| August, 2028 | $79.32 | $77.53 | $90.68 | -35.60% |
| September, 2028 | $80.53 | $76.10 | $83.59 | -34.61% |
| October, 2028 | $89.04 | $79.22 | $89.73 | -27.70% |
| November, 2028 | $90.10 | $86.28 | $93.49 | -26.85% |
| December, 2028 | $86.87 | $85.70 | $94.57 | -29.47% |
State Street Spdr S P Biotech Etf Stock (XBI) Price Forecast for 2029
The 2029 price forecast for State Street Spdr S P Biotech Etf Stock (XBI) is $87.34 on average, with a high prediction of $107.21 and a low estimate of $67.48. This represents an -29.08% decrease from the previous price of $123.17.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $87.96 | $84.49 | $90.50 | -28.58% |
| February, 2029 | $82.36 | $79.58 | $87.40 | -33.13% |
| March, 2029 | $80.79 | $80.41 | $84.96 | -34.41% |
| April, 2029 | $73.28 | $71.99 | $81.12 | -40.50% |
| May, 2029 | $70.63 | $67.48 | $75.76 | -42.65% |
| June, 2029 | $81.51 | $68.67 | $81.52 | -33.82% |
| July, 2029 | $92.97 | $80.89 | $95.70 | -24.51% |
| August, 2029 | $91.12 | $89.69 | $98.00 | -26.02% |
| September, 2029 | $98.44 | $90.07 | $99.18 | -20.08% |
| October, 2029 | $97.25 | $95.84 | $107.21 | -21.04% |
| November, 2029 | $86.52 | $84.95 | $99.58 | -29.75% |
| December, 2029 | $90.88 | $84.83 | $94.94 | -26.22% |
State Street Spdr S P Biotech Etf Stock (XBI) Price Forecast for 2030
State Street Spdr S P Biotech Etf Stock (XBI) is expected to reach an average price of $88.00 in 2030, with a high forecast of $105.92 and a low forecast of $70.08. This signifies an -28.55% decrease from the last price of $123.17.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $88.92 | $86.41 | $91.93 | -27.81% |
| February, 2030 | $93.01 | $88.55 | $96.36 | -24.48% |
| March, 2030 | $91.09 | $90.43 | $94.80 | -26.05% |
| April, 2030 | $87.22 | $85.50 | $92.16 | -29.19% |
| May, 2030 | $83.47 | $82.74 | $91.22 | -32.23% |
| June, 2030 | $88.46 | $80.09 | $89.05 | -28.18% |
| July, 2030 | $95.13 | $87.80 | $95.42 | -22.76% |
| August, 2030 | $103.76 | $96.52 | $104.10 | -15.76% |
| September, 2030 | $102.16 | $98.96 | $105.92 | -17.05% |
| October, 2030 | $104.22 | $95.18 | $105.15 | -15.38% |
| November, 2030 | $79.48 | $74.59 | $105.90 | -35.47% |
| December, 2030 | $81.43 | $70.08 | $86.39 | -33.89% |
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):